TOLERA trial in RA RTX/ABA sequence versus RTX alone 10pts each group Primary outcome was ambitious: ACPA seroconversion No difference between ttmts (and also no seroconversion) No diff in disease activity No diff in ACPA change wt wk52 @RheumNow OP0069 #EULAR2024 https://t.co/0EM7XRzfNo